| Treatment period (weeks) | Post-treatment period (weeks) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
 | SD1 | 2 | 6 | 10 | 14 | 18 | 22 | 26 | 34 | 42 | 52 | 4 |
Efficacy and safety assessments* | Â | X | X | X | X | X | X | X | X | X | X | X |
IBDQ assessment | X | Â | Â | Â | Â | Â | Â | X | Â | Â | X | Â |
CDAI assessment | X | X | X | X | X | X | X | X | X | X | X | Â |
CRP | X | Â | X | Â | X | Â | X | X | X | X | X | X |
ESR | X | Â | X | Â | X | Â | X | X | X | X | X | X |
Antibodies to IFN beta-1a | X | Â | Â | Â | Â | Â | Â | X | Â | Â | X | Â |
Thyroid function | X | Â | Â | Â | Â | Â | Â | X | Â | Â | X | Â |
Urinalysis | X | Â | Â | Â | Â | Â | Â | X | Â | Â | X | X |
Pregnancy testing | X | Â | Â | X | Â | X | Â | X | Â | Â | X | Â |